Denali Therapeutics Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsDenali Therapeutics is a clinical-stage biotech transitioning to a commercial company with its first FDA-approved product, AVLAYAH, for Hunter syndrome, and a TransportVehicle platform for CNS and rare diseases.
What they do
Denali discovers and develops biotherapeutics using its proprietary TransportVehicle (TV) platform to cross the blood-brain barrier. The company's pipeline includes tividenofusp alfa (AVLAYAH), an approved enzyme replacement therapy for Hunter syndrome (MPS II), and clinical candidates for Sanfilippo syndrome type A, frontotemporal dementia, Alzheimer's disease, and Pompe disease. Its TV franchises include Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV) to deliver large molecules to the brain and other tissues.
Revenue drivers
- AVLAYAH (tividenofusp alfa-eknm) — First and only approved product; FDA-approved for neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients. Generated $3.6M net product revenue in Q2 2026, with management projecting $10-12M for Q3 2026.
- Collaborations and licensing — The 10-K references strategic collaborations as potential future revenue sources, but no collaboration revenue is reported in the provided figures for recent periods.
Recent performance
In Q2 2026, the company reported $3.6M in net product revenue from AVLAYAH, its first reported product sales following an April 2026 FDA accelerated approval. The company had zero revenue in 2024 and 2025, with net losses of $422.8M and $512.5M respectively. Operating cash flow remained negative at -$412.6M in 2025. As of June 30, 2026, total assets were $1.16B, cash and equivalents were $201.5M, and the company raised $195M in gross proceeds in July 2026 from the sale of a Priority Review Voucher.
Strategy
Denali's 'D3X3' strategy (2026-2028) aims to deliver two commercial brands—AVLAYAH and zafinofusp alfa (DNL126)—and achieve five clinical proof-of-concept readouts across its portfolio. The company is building a commercial infrastructure for rare disease launches and plans to advance 4-6 additional TV-enabled programs into the clinic. Management priorities include expanding the AVLAYAH label to adults, pursuing global regulatory submissions, and broadening the pipeline in Alzheimer's and Parkinson's disease.
Risks
- Commercial execution risk — AVLAYAH is the first product launch; if the company cannot scale reimbursement, patient access, or manufacturing, revenue will fall short of projections.
- Regulatory and label limitations — AVLAYAH holds accelerated approval only for pediatric patients before advanced neurologic impairment; failure to generate confirmatory evidence could affect long-term approval.
- Clinical pipeline failure — Dependence on early-stage candidates for rare and CNS diseases facing high trial failure risk; delays in the zafinofusp alfa BLA submission could impair the rare disease franchise.
- Capital and cash burn — The company has consistently negative operating cash flow and net losses above $400M annually, requiring ongoing capital raises or non-dilutive funding to sustain operations.
Outlook
Management projects Q3 2026 AVLAYAH net product revenue of $10-12M and expects a zafinofusp alfa BLA submission in 2027 with potential accelerated approval. The company has pro forma cash above $1.1 billion following the July 2026 Priority Review Voucher sale, extending its runway. The COMPASS study for AVLAYAH is ongoing to support label expansion to adults and global filings.